Answers are grounded in this paper and cite their sources.
Demonstrates bioorthogonal organelle membrane labeling, suggesting a new approach for cellular imaging and therapy.
Organelle membranes are fundamental interfaces that enable specialized cellular functions. Achieving organelle membrane labeling with small-molecule fluorescent probes remains highly desirable yet challenging. Here, we report a robust bioorthogonal platform based on fluorogenic tetrazine-cyanine (TBCy) probes, constructed by integrating tetrazine into a tunable BF2-bridged cyanine (BCy) scaffold, to develop a generalizable organelle membrane labeling strategy. The TBCy probes exhibit outstanding fluorogenicity, robust photostability, red-to-near-infrared absorption/emission, and charge neutrality. Coupling with rationally designed organelle membrane-targeted probes, the biocompatible TBCy variants enable no-wash, high-specificity labeling of lysosomal, mitochondrial, and endoplasmic reticulum membranes. This capability facilitates multicolor super-resolution STED imaging and the real-time tracking of their dynamics. Moreover, through bioorthogonal activation, photosensitized TBCy allows spatiotemporally controlled disruption of the lysosomal membrane under light irradiation, leading to lysosomal membrane damage-triggered cell death. This work not only provides a versatile toolbox for organelle membrane function elucidation and manipulation but also expands the design and application scope of fluorogenic tetrazine probes in precise bioimaging and therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: